Investing in the Future

Methuselah Foundation continuously and vigorously scans the horizons for high impact efforts that meet all of our criteria and show significant promise for extending healthy human life and eliminating the diseases of aging.

We are currently providing support for these companies working in research and development of long term life extension solutions.

Organovo, Inc. is a regenerative medicine company that applies proprietary technology to "print" new organs. Their work will enable us to quickly and cheaply produce organs and body tissue for transplantation and testing, thereby reducing the need for animal test subjects and greatly speeding up the process by which treatments can used for humans.

By marrying a knowledge of biophysics and cell biology with the precision of computer aided design and high precision deposition, Organovo is able to recreate the microarchitecture of even the most complex human tissue. By precisely placing cells with an organ printer, and providing them with the proper natural developmental cues, the cells do exactly what they do in nature: they self assemble into fully formed, functional tissue. Learn more about Bioprinting Technology here.

The SENS Foundation research programs invest directly into specific scientific research, aimed at the biomedical repair of the damage of biological aging. Using a revolutionary "engineering" approach, these therapies will repair all known forms of aging-related damage in the human body, with the aim of restoring youthful cellular and biomolecular structure, renewing youthful function, health, and vitality. Listen to Aubrey de Grey explain the SENS approach here.

SENS Foundation was launched in March, 2009 as a new and independent organization (prior to that it was part of the Methuselah Foundation), with a mission to develop, promote and ensure widespread access to regenerative medicine solutions to the disabilities and diseases of aging and the Methuselah Foundation subsequently transferred its SENS research initiatives, along with supportive grant funding, to SENS Foundation.

To learn more about the SENS solution visit SENS.org.

Methuselah Foundation supports the development of ultra-high throughput low-cost DNA sequencing technology via the leading edge genomics company Halcyon Molecular. By making DNA sequencing significantly faster, cheaper, more accurate, and more comprehensive, Halcyon intends to significantly increase the scope and depth of genetic research, accelerating the development of biotechnologies that improve health and longevity.

Silverstone Solutions delivers efficient, cost-effective technology solutions to the medical and healthcare industries. The flagship product, Matchmaker, is a clinical application that allows hospitals and transplant organizations to more quickly and accurately match patients in need of kidney transplants who have a qualified, incompatible donor with an alternate compatible donor. The software utilizes a series of proprietary algorithms to generate all potential paired donations and also optimizes the greatest number of possible transplants for an entire pool of paired-exchange candidates.